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correlations of 0.41 for FC and 0.42 for RI) were good to excel-
lent. The three scores were predictive of the unwillingness to be
treated with insulin and to step up insulin treatment (AUC
ranging from 0.65 to 0.87). The AM score was predictive of the
switch to an insulin treatment and increased numbers of injec-
tions at the end of baseline visit (AUC of 0.80 and 0.66). CON-
CLUSION: The questionnaires are reliable, valid and a help for
physicians in assessing the hurdles faced by diabetic patients
starting or stepping up insulin treatments.
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OBJECTIVES: To evaluate the patterns and predictors of adher-
ence to statin therapy in all patients with diabetes in the com-
munity. METHODS: We retrospectively studied patients with
type 1 and type 2 diabetes who were resident in Tayside, Scot-
land from 1st January 1993 to 31st May 2003, with at least 6
months of prescriptions of statins. The main outcome measure
was an adherence index. The inﬂuence of several covariates
including age, sex, duration of diabetes, adherence to diabetes
medication and co-morbidities were also assessed. RESULTS: A
total of 5010 patients were included in the study: 4816 with type
2 diabetes and 194 with type 1 diabetes. Median statin adher-
ence was 75% and 77% in type 1 and 2 diabetes respectively,
with a similar distribution in both groups. There were 35% of
type 1’s and 42% of type 2’s with adequate adherence (°Y´80%).
Predictors of adequate adherence in type 2 diabetes were being
older, being an ex-smoker compared to never having smoked,
better adherence to diabetic medication, a lower HbA1c level,
shorter duration of statin therapy, a history of coronary heart
disease, a history of stroke and being prescribed concurrent med-
ication for cardiovascular disease. Conversely, patients pre-
scribed concurrent asthma medication were less adherent to their
statin medication. In type 1 diabetes signiﬁcant predictors were
better adherence to diabetic medication, a lower HbA1c level,
being female and being prescribed concurrent medication for car-
diovascular disease. CONCLUSIONS: Approximately 65% of
type 1 patients and 58% of type 2 patient collected less than
80% of their medically recommended dose of statins. Given 
the increased risk of coronary heart disease facing patients with
diabetes this poor adherence could have signiﬁcant health 
implications.
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OBJECTIVES: Conversion of type 2 diabetic patients previously
treated with a conventional insulin regiment treatment to a com-
bined oral treatment with pioglitazone and glimepiride has been
shown to improve resistance and not to result in an overall dete-
rioration of metabolic control. Thus this study was performed
to evaluate the impact of this conversion on patients’ quality of
life. METHODS: A sample of 116 type 2 diabetic patients (73
men, 43 women; age (mean ± SD) 59.43 ± 9.3 years) were con-
verted as aforementioned. Quality of life was measured by using
the EQ-5D questionnaire (consisting of a ﬁve-question-survey
and the Visual Analogue Scale) and the disease-speciﬁc QSD-R
questionnaire, both at baseline and after six months. Based on
statistical analyses (descriptive statistics, paired t-test, multivari-
ate linear regression model) factors inﬂuencing quality of life
scores were identiﬁed. RESULTS: Overall high quality of life
levels at baseline as well as after six month were measured.
Despite these positive results both questionnaires identiﬁed prob-
lems in the dimensions “pain/ discomfort”/ “physical com-
plaints” and “anxiety/ depression”. The mean EQ-5D index
score (based on German societal perspective) increased from
84.82 to 85.66 (p = 0.660), whereas the mean EQ-VAS score
(patient perspective) increased from 70.72 to 72.88 (p = 0.235).
Mean QSD-R score improved from a global stress score of 0.76
at baseline to 0.70 six months later (p = 0.223). Research results
presented improvements in all dimensions measured. Multiple
regression analysis as well as a subgroup-analysis demonstrated
that a decreasing BMI, a lower duration of disease and male
gender have a positive effect on quality of life. CONCLUSIONS:
The mean quality of life scores did not change signiﬁcantly. The
conversion from insulin to a combined oral treatment with
pioglitazone and glimepiride is possible without deterioration of
health related quality of life.
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OBJECTIVES: To describe the health-related quality of life
(QoL) of type 2 diabetics by age group, duration of disease,
comorbidities and complications, therapeutic interventions and
HbA1c status. METHODS: DETECT (“Diabetes Cardiovascu-
lar Risk-Evaluation: Targets and Essential Data for Commitment
of Treatment”; http://www.detect-studie.de) is a large-scale,
nationally representative, cross-sectional clinical-epidemiological
study with a prospective-longitudinal component in primary
care. Based on a randomised sample of 3188 physicians, the
health state of 55,519 patients was assessed in a standardised
way in 2003. Frequency of problems in the EQ-5D items mobil-
ity, self-care, usual activities, pain/discomfort and anxiety/
depression as well as the additive total score were analysed in n
= 6558 type 2 diabetics. RESULTS: The most frequent QoL
restrictions were in the domains of pain/discomfort (74.1%) and
mobility (44.3%) followed by daily activities (34.1%),
anxiety/depression (31.4%) and self-care (17.2%). The mean
additive total score was 68.1. That was, after adjustment for age
and gender, signiﬁcantly lower than in nondiabetics (72.4) or in
healthy attendees (81.7). Overall and in each QoL domain, prob-
lems increased if micro- and macrovascular disease was present,
and with the age of patients or duration of diabetes respectively.
There were no signiﬁcant differences between patients with or
without therapy (diet, exercise and oral antidiabetics). However,
patients with insulin and combined therapy had considerably
lower Qol scores, even after adjustment for age, gender, dura-
tion of diabetes and presence of micro- and macro-vascular
disease. HbA1c adjustment had only small effects on the EQ-5D
dimensions. Compared to patients with optimal HbA1c values
(<6%), poorly adjusted patients (HbA1c > 8%) reported signif-
icantly more problems at the dimensions mobility and self-care.
CONCLUSIONS: Our data provide, in unprecedented detail, the
health related QoL of type 2 diabetics in German primary care,
highlighting the association of insulin and combined treatments
with reduced QoL.
